These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22494863)

  • 1. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients.
    Capodanno D; Capranzano P; Giacchi G; Calvi V; Tamburino C
    Int J Cardiol; 2013 Aug; 167(4):1237-41. PubMed ID: 22494863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation and Previous Stroke: A Systematic Review and Meta-Analysis.
    Shi M; Liu L; Wafa H; Curcin V; Wang Y
    Neuroepidemiology; 2024; 58(1):1-14. PubMed ID: 37848006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis.
    Zhuo X; Wang J; Shao L
    Cardiovasc Drugs Ther; 2024 Feb; 38(1):79-89. PubMed ID: 35763193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    Miller CS; Grandi SM; Shimony A; Filion KB; Eisenberg MJ
    Am J Cardiol; 2012 Aug; 110(3):453-60. PubMed ID: 22537354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
    Ruff CT; Giugliano RP; Braunwald E; Hoffman EB; Deenadayalu N; Ezekowitz MD; Camm AJ; Weitz JI; Lewis BS; Parkhomenko A; Yamashita T; Antman EM
    Lancet; 2014 Mar; 383(9921):955-62. PubMed ID: 24315724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis.
    Mitchell SA; Simon TA; Raza S; Jakouloff D; Orme ME; Lockhart I; Drost P
    Clin Appl Thromb Hemost; 2013; 19(6):619-31. PubMed ID: 23698729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin.
    Dogliotti A; Paolasso E; Giugliano RP
    Clin Cardiol; 2013 Feb; 36(2):61-7. PubMed ID: 23338902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis.
    Fu W; Guo H; Guo J; Lin K; Wang H; Zhang Y; Wang Y; Shan Z
    J Cardiovasc Med (Hagerstown); 2014 Dec; 15(12):873-9. PubMed ID: 25304034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
    Bruins Slot KM; Berge E
    Cochrane Database Syst Rev; 2013 Aug; (8):CD008980. PubMed ID: 23925867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
    Testa L; Agnifili M; Latini RA; Mattioli R; Lanotte S; De Marco F; Oreglia J; Latib A; Pizzocri S; Laudisa ML; Brambilla N; Bedogni F
    QJM; 2012 Oct; 105(10):949-57. PubMed ID: 22771555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
    Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
    Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons.
    Sardar P; Chatterjee S; Wu WC; Lichstein E; Ghosh J; Aikat S; Mukherjee D
    PLoS One; 2013; 8(10):e77694. PubMed ID: 24204920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation.
    Baker WL; Phung OJ
    Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):711-9. PubMed ID: 22912382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups.
    Gómez-Outes A; Terleira-Fernández AI; Calvo-Rojas G; Suárez-Gea ML; Vargas-Castrillón E
    Thrombosis; 2013; 2013():640723. PubMed ID: 24455237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
    Chatterjee S; Sardar P; Giri JS; Ghosh J; Mukherjee D
    Mayo Clin Proc; 2014 Jul; 89(7):896-907. PubMed ID: 24996233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oral anticoagulants for atrial fibrillation.
    Hankey GJ; Eikelboom JW
    Curr Atheroscler Rep; 2013 Aug; 15(8):344. PubMed ID: 23761015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.